Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules

Percentage of Subjects With Detectable TBE Antibody Titers Greater Than or Equal to (≥) 2

Antibody titers were measured by GlaxoSmithKline (GSK) neutralizing antibody (NT) assay.

Time frame: At Year 6

Percentage of Subjects With Detectable TBE Antibody Titers ≥ 2

Antibody titers were measured by GSK NT assay.

Time frame: At Year 7

Percentage of Subjects With Detectable TBE Antibody Titers ≥ 2

Antibody titers were measured by GSK NT assay.

Time frame: At Year 8

Percentage of Subjects With Detectable TBE Antibody Titers ≥ 2

Antibody titers were measured by GSK NT assay.

Time frame: At Year 9

Percentage of Subjects With Detectable TBE Antibody Titers ≥ 2

Antibody titers were measured by GSK NT assay.

Time frame: At Year 10

Percentage of Subjects With Detectable TBE Antibody Titers ≥ 10

Antibody titers were measured by GSK NT assay.

Time frame: At Year 6

Percentage of Subjects With Detectable TBE Antibody Titers ≥ 10

Antibody titers were measured by GSK NT assay.

Time frame: At Year 7

Percentage of Subjects With Detectable TBE Antibody Titers ≥ 10

Antibody titers were measured by GSK NT assay.

Time frame: At Year 8

Percentage of Subjects With Detectable TBE Antibody Titers ≥ 10

Antibody titers were measured by GSK NT assay.

Time frame: At Year 9

Percentage of Subjects With Detectable TBE Antibody Titers ≥ 10

Antibody titers were measured by GSK NT assay.

Time frame: At Year 10

Evaluation of Geometric Mean Antibody Titers (GMTs)

GMTs by visit were tabulated for each vaccine schedule. Baselines pre booster and post booster vaccination titers were used as denominators to calculate Geometric Mean Ratios (GMRs). Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start). Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 6

Evaluation of GMTs

GMTs by visit were tabulated for each vaccine schedule. Baselines pre booster and post booster vaccination titers were used as denominators to calculate GMRs. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start). Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 7

Evaluation of GMTs

GMTs by visit were tabulated for each vaccine schedule. Baselines pre booster and post booster vaccination titers were used as denominators to calculate GMRs. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start). Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At year 8

Evaluation of GMTs

GMTs by visit were tabulated for each vaccine schedule. Baselines pre booster and post booster vaccination titers were used as denominators to calculate GMRs. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start). Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 9

Evaluation of GMTs

GMTs by visit were tabulated for each vaccine schedule. Baselines pre booster and post booster vaccination titers were used as denominators to calculate GMRs. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start). Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 10

Geometric Mean Ratios (GMRs) Calculated to Pre Booster Baselines

GMR values were tabulated by vaccine schedule using pre booster vaccination titers as baseline. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start).

Time frame: At Year 6

GMRs Calculated to Pre Booster Baselines

GMR values were tabulated by vaccine schedule using pre booster vaccination titers as baseline. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start).

Time frame: At Year 7

GMRs Calculated to Pre Booster Baselines

GMR values were tabulated by vaccine schedule using pre booster vaccination titers as baseline. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start).

Time frame: At Year 8

GMRs Calculated to Pre Booster Baselines

GMR values were tabulated by vaccine schedule using pre booster vaccination titers as baseline. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start).

Time frame: At Year 9

GMRs Calculated to Pre Booster Baselines

GMR values were tabulated by vaccine schedule using pre booster vaccination titers as baseline. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start).

Time frame: At Year 10

GMRs Calculated to Post Booster Baselines

GMR values were tabulated by vaccine schedule using post booster vaccination titers as baseline. Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 6

GMRs Calculated to Post Booster Baselines

GMR values were tabulated by vaccine schedule using post booster vaccination titers as baseline. Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 7

GMRs Calculated to Post Booster Baselines

GMR values were tabulated by vaccine schedule using post booster vaccination titers as baseline. Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 8

GMRs Calculated to Post Booster Baselines

GMR values were tabulated by vaccine schedule using post booster vaccination titers as baseline. Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 9

GMRs Calculated to Post Booster Baselines

GMR values were tabulated by vaccine schedule using post booster vaccination titers as baseline. Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 10

Percentage of Subjects With Detectable TBE Antibody Titers ≥ 2 by Age Groups

Age groups defined based on age at entry to V48P7E1 study: 15 to 49 years, ≥ 50 years, and ≥ 60 years.

Time frame: At Year 6

Percentage of Subjects With Detectable TBE Antibody Titers ≥ 2 by Age Groups

Age groups defined based on age at entry to V48P7E1 study: 15 to 49 years, ≥ 50 years, and ≥ 60 years.

Time frame: At Year 7

Percentage of Subjects With Detectable TBE Antibody Titers ≥ 2 by Age Groups

Age groups defined based on age at entry to V48P7E1 study: 15 to 49 years, ≥ 50 years, and ≥ 60 years.

Time frame: At Year 8

Percentage of Subjects With Detectable TBE Antibody Titers ≥ 2 by Age Groups

Age groups defined based on age at entry to V48P7E1 study: 15 to 49 years, ≥ 50 years, and ≥ 60 years.

Time frame: At Year 9

Percentage of Subjects With Detectable TBE Antibody Titers ≥ 2 by Age Groups

Age groups defined based on age at entry to V48P7E1 study: 15 to 49 years, ≥ 50 years, and ≥ 60 years.

Time frame: At Year 10

Percentage of Subjects With Detectable TBE Antibody Titers ≥ 10 by Age Groups

Age groups defined based on age at entry to V48P7E1 study: 15 to 49 years, ≥ 50 years, and ≥ 60 years.

Time frame: At Year 6

Percentage of Subjects With Detectable TBE Antibody Titers ≥ 10 by Age Groups

Age groups defined based on age at entry to V48P7E1 study: 15 to 49 years, ≥ 50 years, and ≥ 60 years.

Time frame: At Year 7

Percentage of Subjects With Detectable TBE Antibody Titers ≥ 10 by Age Groups

Age groups defined based on age at entry to V48P7E1 study: 15 to 49 years, ≥ 50 years, and ≥ 60 years.

Time frame: At Year 8

Percentage of Subjects With Detectable TBE Antibody Titers ≥ 10 by Age Groups

Age groups defined based on age at entry to V48P7E1 study: 15 to 49 years, ≥ 50 years, and ≥ 60 years.

Time frame: At Year 9

Percentage of Subjects With Detectable TBE Antibody Titers ≥ 10 by Age Groups

Age groups defined based on age at entry to V48P7E1 study: 15 to 49 years, ≥ 50 years, and ≥ 60 years.

Time frame: At Year 10

Evaluation of GMTs in the Age Group of 15-49 Years

GMTs by visit were tabulated for each vaccine schedule. Baselines pre booster and post booster vaccination titers were used as denominators to calculate GMRs. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start). Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 6

Evaluation of GMTs in the Age Group of 15-49 Years

GMTs by visit were tabulated for each vaccine schedule. Baselines pre booster and post booster vaccination titers were used as denominators to calculate GMRs. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start). Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 7

Evaluation of GMTs in the Age Group of 15-49 Years

GMTs by visit were tabulated for each vaccine schedule. Baselines pre booster and post booster vaccination titers were used as denominators to calculate GMRs. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start). Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 8

Evaluation of GMTs in the Age Group of 15-49 Years

GMTs by visit were tabulated for each vaccine schedule. Baselines pre booster and post booster vaccination titers were used as denominators to calculate GMRs. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start). Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 9

Evaluation of GMTs in the Age Group of 15-49 Years

GMTs by visit were tabulated for each vaccine schedule. Baselines pre booster and post booster vaccination titers were used as denominators to calculate GMRs. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start). Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 10

Evaluation of GMTs in the Age Group of ≥ 50 Years

GMTs by visit were tabulated for each vaccine schedule. Baselines pre booster and post booster vaccination titers were used as denominators to calculate GMRs. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start). Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 6

Evaluation of GMTs in the Age Group of ≥ 50 Years

GMTs by visit were tabulated for each vaccine schedule. Baselines pre booster and post booster vaccination titers were used as denominators to calculate GMRs. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start). Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 7

Evaluation of GMTs in the Age Group of ≥ 50 Years

GMTs by visit were tabulated for each vaccine schedule. Baselines pre booster and post booster vaccination titers were used as denominators to calculate GMRs. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start). Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 8

Evaluation of GMTs in the Age Group of ≥ 50 Years

GMTs by visit were tabulated for each vaccine schedule. Baselines pre booster and post booster vaccination titers were used as denominators to calculate GMRs. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start). Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 9

Evaluation of GMTs in the Age Group of ≥ 50 Years

GMTs by visit were tabulated for each vaccine schedule. Baselines pre booster and post booster vaccination titers were used as denominators to calculate GMRs. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start). Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 10

Evaluation of GMTs in the Age Group of ≥ 60 Years

GMTs by visit were tabulated for each vaccine schedule. Baselines pre booster and post booster vaccination titers were used as denominators to calculate GMRs. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start). Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 6

Evaluation of GMTs in the Age Group of ≥ 60 Years

GMTs by visit were tabulated for each vaccine schedule. Baselines pre booster and post booster vaccination titers were used as denominators to calculate GMRs. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start). Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 7

Evaluation of GMTs in the Age Group of ≥ 60 Years

GMTs by visit were tabulated for each vaccine schedule. Baselines pre booster and post booster vaccination titers were used as denominators to calculate GMRs. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start). Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 8

Evaluation of GMTs in the Age Group of ≥ 60 Years

GMTs by visit were tabulated for each vaccine schedule. Baselines pre booster and post booster vaccination titers were used as denominators to calculate GMRs. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start). Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 9

Evaluation of GMTs in the Age Group of ≥ 60 Years

GMTs by visit were tabulated for each vaccine schedule. Baselines pre booster and post booster vaccination titers were used as denominators to calculate GMRs. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start). Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 10

GMRs Calculated to Pre Booster Baselines in the Age Group of 15-49 Years

GMR values were tabulated by vaccine schedule using pre booster vaccination titers as baseline. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start).

Time frame: At Year 6

GMRs Calculated to Pre Booster Baselines in the Age Group of 15-49 Years

GMR values were tabulated by vaccine schedule using pre booster vaccination titers as baseline. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start).

Time frame: At Year 7

GMRs Calculated to Pre Booster Baselines in the Age Group of 15-49 Years

GMR values were tabulated by vaccine schedule using pre booster vaccination titers as baseline. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start).

Time frame: At Year 8

GMRs Calculated to Pre Booster Baselines in the Age Group of 15-49 Years

GMR values were tabulated by vaccine schedule using pre booster vaccination titers as baseline. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start).

Time frame: At Year 9

GMRs Calculated to Pre Booster Baselines in the Age Group of 15-49 Years

GMR values were tabulated by vaccine schedule using pre booster vaccination titers as baseline. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start).

Time frame: At Year 10

GMRs Calculated to Pre Booster Baselines in the Age Group of ≥ 50 Years

GMR values were tabulated by vaccine schedule using pre booster vaccination titers as baseline. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start).

Time frame: At Year 6

GMRs Calculated to Pre Booster Baselines in the Age Group of ≥ 50 Years

GMR values were tabulated by vaccine schedule using pre booster vaccination titers as baseline. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start).

Time frame: At Year 7

GMRs Calculated to Pre Booster Baselines in the Age Group of ≥ 50 Years

GMR values were tabulated by vaccine schedule using pre booster vaccination titers as baseline. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start).

Time frame: At Year 8

GMRs Calculated to Pre Booster Baselines in the Age Group of ≥ 50 Years

GMR values were tabulated by vaccine schedule using pre booster vaccination titers as baseline. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start).

Time frame: At Year 9

GMRs Calculated to Pre Booster Baselines in the Age Group of ≥ 50 Years

GMR values were tabulated by vaccine schedule using pre booster vaccination titers as baseline. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start).

Time frame: At Year 10

GMRs Calculated to Pre Booster Baselines in the Age Group of ≥ 60 Years

GMR values were tabulated by vaccine schedule using pre booster vaccination titers as baseline. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start).

Time frame: At Year 6

GMRs Calculated to Pre Booster Baselines in the Age Group of ≥ 60 Years

GMR values were tabulated by vaccine schedule using pre booster vaccination titers as baseline. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start).

Time frame: At Year 7

GMRs Calculated to Pre Booster Baselines in the Age Group of ≥ 60 Years

GMR values were tabulated by vaccine schedule using pre booster vaccination titers as baseline. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start).

Time frame: At Year 8

GMRs Calculated to Pre Booster Baselines in the Age Group of ≥ 60 Years

GMR values were tabulated by vaccine schedule using pre booster vaccination titers as baseline. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start).

Time frame: At Year 9

GMRs Calculated to Pre Booster Baselines in the Age Group of ≥ 60 Years

GMR values were tabulated by vaccine schedule using pre booster vaccination titers as baseline. Pre booster vaccination titer: GMT at Day 0 of V48P7E1 prior to booster vaccine administration (excluding subjects who received the booster before V48P7E1 study start).

Time frame: At Year 10

GMRs Calculated to Post Booster Baselines in the Age Group of 15-49 Years

GMR values were tabulated by vaccine schedule using post booster vaccination titers as baseline. Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 6

GMRs Calculated to Post Booster Baselines in the Age Group of 15-49 Years

GMR values were tabulated by vaccine schedule using post booster vaccination titers as baseline. Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 7

GMRs Calculated to Post Booster Baselines in the Age Group of 15-49 Years

GMR values were tabulated by vaccine schedule using post booster vaccination titers as baseline. Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 8

GMRs Calculated to Post Booster Baselines in the Age Group of 15-49 Years

GMR values were tabulated by vaccine schedule using post booster vaccination titers as baseline. Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 9

GMRs Calculated to Post Booster Baselines in the Age Group of 15-49 Years

GMR values were tabulated by vaccine schedule using post booster vaccination titers as baseline. Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 10

GMRs Calculated to Post Booster Baselines in the Age Group of ≥ 50 Years

GMR values were tabulated by vaccine schedule using post booster vaccination titers as baseline. Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 6

GMRs Calculated to Post Booster Baselines in the Age Group of ≥ 50 Years

GMR values were tabulated by vaccine schedule using post booster vaccination titers as baseline. Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 7

GMRs Calculated to Post Booster Baselines in the Age Group of ≥ 50 Years

GMR values were tabulated by vaccine schedule using post booster vaccination titers as baseline. Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 8

GMRs Calculated to Post Booster Baselines in the Age Group of ≥ 50 Years

GMR values were tabulated by vaccine schedule using post booster vaccination titers as baseline. Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 9

GMRs Calculated to Post Booster Baselines in the Age Group of ≥ 50 Years

GMR values were tabulated by vaccine schedule using post booster vaccination titers as baseline. Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 10

GMRs Calculated to Post Booster Baselines in the Age Group of ≥ 60 Years

GMR values were tabulated by vaccine schedule using post booster vaccination titers as baseline. Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 6

GMRs Calculated to Post Booster Baselines in the Age Group of ≥ 60 Years

GMR values were tabulated by vaccine schedule using post booster vaccination titers as baseline. Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 7

GMRs Calculated to Post Booster Baselines in the Age Group of ≥ 60 Years

GMR values were tabulated by vaccine schedule using post booster vaccination titers as baseline. Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 8

GMRs Calculated to Post Booster Baselines in the Age Group of ≥ 60 Years

GMR values were tabulated by vaccine schedule using post booster vaccination titers as baseline. Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 9

GMRs Calculated to Post Booster Baselines in the Age Group of ≥ 60 Years

GMR values were tabulated by vaccine schedule using post booster vaccination titers as baseline. Post booster vaccination titer: GMT at Day 21 of V48P7E1 (for subjects who received booster in V48P7E1); Day 0 for subjects who received booster before V48P7E1 study start.

Time frame: At Year 10